Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
- Nuvation Bio focuses on cancer therapies, acquiring advanced pipeline candidate taletrectinib. - Taletrectinib has Breakthrough Therapy Designation and promising clinical activity. - NUVB also acquired rights to an IDH1 inhibitor and is developing a drug-drug conjugate. Price Impact Rating: Bullish Impact Horizon Rating: Long-term Type: Research Analysis
View signal analysis